Institutional members access full text with Ovid®

Share this article on:

Intravenous fluids in sepsis: what to use and what to avoid

Karakala, Nithina; Raghunathan, Karthikb; Shaw, Andrew D.b

Current Opinion in Critical Care: December 2013 - Volume 19 - Issue 6 - p 537–543
doi: 10.1097/MCC.0000000000000028
RENAL SYSTEM: Edited by Ravindra L. Mehta

Purpose of review Septic shock is one of the most common and life-threatening conditions afflicting critically ill patients. Intravenous volume resuscitation is considered an initial and very important step in management. The most suitable fluid for volume expansion during septic shock remains unclear. In this review, we focus on the benefits and adverse effects of the most commonly used intravenous fluids in critically ill septic patients.

Recent findings The debate about the benefits of colloids over crystalloids has been ongoing for the last few decades. With recent literature showing apparent harm from the use of hydroxyethyl starches (HESs), and given the growing concerns of adverse renal and acid–base abnormalities associated with 0.9% saline compared with balanced crystalloid solutions, it may be time to change the nature of the ‘fluid debate’.

Summary Crystalloids should still be considered as the first-choice drug for volume resuscitation in patients with septic shock. Colloids such as albumin can be considered in some clinical settings. HES should be avoided. Balanced crystalloids might have an important role to play in the management of septic shock.

aDivision of Nephrology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina

bDepartment of Anesthesiology, Duke University Medical Center, Durham VAMC, Durham, North Carolina, USA

Correspondence to Andrew D. Shaw, MBBS, FRCA, FCCM, Associate Professor, Department of Anesthesiology and Critical Care Medicine, Duke University Medical Center, Durham VAMC, Durham, North Carolina, USA. Tel: +1 919 286 0411 x5091; fax: +1 919 286 6853; e-mail: andrew.shaw@duke.edu

© 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins